Clinical Trials Logo

End Stage Renal Disease clinical trials

View clinical trials related to End Stage Renal Disease.

Filter by:

NCT ID: NCT00179205 Terminated - Clinical trials for End Stage Renal Disease

Complementary Intradialytic Nutritional Supplementation in Dialysis Patients

Start date: May 2005
Phase: Phase 2
Study type: Interventional

In this study, the investigators hypothesize that long-term administration of adequate intradialytic oral nutritional supplementation will increase visceral protein concentrations and somatic protein stores in malnourished chronic hemodialysis patients.

NCT ID: NCT00131872 Terminated - Clinical trials for End Stage Renal Disease

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Start date: March 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish the substantial equivalence of Expedial and ePTFE grafts for effectiveness in maintaining primary or assisted primary patency.

NCT ID: NCT00023244 Terminated - Clinical trials for End-Stage Renal Disease

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Start date: January 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday). Graft survival has improved in recent years in children with kidney transplants. One bad side effect of steroid maintenance therapy has been growth retardation. Doctors believe steroids might be safely withdrawn in patients that are receiving other maintenance therapies. If steroids are removed, children might catch up in their growth and also might have fewer side effects of other kinds. This study evaluates whether steroid therapy can be withdrawn in a way that does not increase graft rejection.

NCT ID: NCT00005113 Terminated - Clinical trials for Kidney Transplantation

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Start date: July 1999
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare treatment with the new drug sirolimus (SRL) versus the standard treatment with cyclosporine (CsA) or tacrolimus in children who have received kidney transplants. SRL is a new medication that may prevent the body's immune system from rejecting organ transplants. After receiving a kidney transplant, the body recognizes the donated kidney as a foreign invader and triggers the immune system to attack the kidney. This can lead to rejection of the new kidney and a failed transplant. To help reduce the risk of kidney rejection, transplant patients are given immunosuppressant drugs, which reduce the body's normal immune response and allow the transplanted organ to function. CsA or tacrolimus are two drugs that are often given to transplant patients. However, these are powerful drugs, and it can cause serious side effects and put a patient at increased risk for infections. SRL is a new drug that has been shown to reduce a transplant patient's chance of rejecting a new kidney, without serious side effects. This study is necessary to test the safety and effectiveness of SRL in children.